Dr. Mathias Frederiksen

Dr. Mathias Frederiksen, is a Principal at the Novartis Venture Fund in Basel, Switzerland. Prior to joining NVF, he was a Group Leader at the Novartis Institutes of Biomedical Research (NIBR), where he established a new group, Chromatin Chemical Biology (within the Chemical Biology and Therapeutics Department) focused on elucidating the role of epigenetic regulation in human disease to uncover novel paradigms for chromatin-focused drug discovery. During this time, he was also a member of the portfolio management and strategy team for the Chemical Biology and Therapeutics Group and had leadership roles on numerous open innovation projects. Before that, he was a Senior Investigator and Lab Head in the Chemical Genetics, Global Discovery Chemistry Group and, before that, a Lab Head for the Neuroscience, Global Discovery Chemistry Group at NIBR. Mathias received his B.Sc in Chemistry from Mount Allison University in Canada, his PhD in synthetic organic chemistry from Imperial College, UK and was a GSK Postdoctoral Fellow at Stanford University.